EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer

Khrystany T Isebia iD, Anouk C de Jong iD, Lisanne F van Dessel, Vanja de Weerd, Corine Beaufort, Jean Helmijr, José Alberto Nakauma-González iD, Job van Riet, Paul Hamberg, Daniel Vis, Michiel S van der Heijden, Nick Beije und 6 weitere

Molecular Oncology · 2025

DOI: 10.1002/1878-0261.13797 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Molecular Oncology, 2025. Verfasst von Khrystany T Isebia und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Aneuploidy, Biomarkers, Tumor, Prostatic Neoplasms, Castration-Resistant, Circulating Tumor DNA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KWF Kankerbestrijding, Hartwig Medical Foundation is a dutch foundation, Center of Personalized Cancer Treatment (CPCT).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cell‐free circulating tumor DNA (ctDNA) has emerged as a promising biomarker for response evaluation in metastatic castration‐resistant prostate cancer (mCRPC). The current study evaluated the modified fast aneuploidy screening test‐sequencing system (mFast‐SeqS), a quick, tumor‐agnostic and affordable ctDNA assay that requires a small input of DNA, to generate a genome‐wide aneuploidy (GWA) score in mCRPC patients, and correlated this to matched metastatic tumor biopsies. In this prospective multicenter study, GWA scores were evaluated from blood samples of 196 mCRPC patients prior to treatment (baseline) with taxanes (docetaxel and cabazitaxel) and androgen receptor signaling inhibitors (ARSI; abiraterone and enzalutamide), and from 74 mCRPC patients at an early timepoint during treatment (early timepoint; median 21 days). Z ‐scores per chromosome arm were tested for their association with tumor tissue genomic alterations. We found that a high tumor load in blood (GWA high ) at baseline was associated with poor response to ARSI [HR: 2.63 (95% CI: 1.86–3.72) P < 0.001] but not to taxanes. Interestingly, GWA high score at the early timepoint was associated with poor response to both ARSIs [HR: 6.73 (95% CI: 2.60–17.42) P < 0.001] and taxanes [2.79 (95% CI: 1.34–5.78) P = 0.006]. A significant interaction in Cox proportional hazards analyses was seen when combining GWA status and type of treatment (at baseline P = 0.008; early timepoint P = 0.018). In summary, detection of ctDNA in blood by mFast‐SeqS is cheap, fast and feasible, and could be used at different timepoints as a potential predictor for outcome to ARSI and taxane treatment in mCRPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AneuploidyBiomarkers, TumorProstatic Neoplasms, Castration-ResistantCirculating Tumor DNACell-Free Nucleic AcidsHumansMaleAgedMiddle AgedProspective StudiesAged, 80 and over

Stichwörter der Autor:innen

abirateronecabazitaxelctDNAdocetaxelenzalutamideprostate cancer

Substanzen

Biomarkers, TumorCirculating Tumor DNACell-Free Nucleic Acids

Autor:innen und Institutionen

  • Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands.
  • Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands.
  • Division of AI in Oncology, German Cancer Research Center (DFKZ), Heidelberg, Germany.
  • Department of Internal Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
  • Department of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

ORCID-Profile: Khrystany T Isebia, Anouk C de Jong, José Alberto Nakauma-González, Teoman Deger, Maurice P H M Jansen, John W M Martens

Förderung

  • KWF Kankerbestrijding
  • Hartwig Medical Foundation is a dutch foundation
  • Center of Personalized Cancer Treatment (CPCT)

Zitieren

APA

Isebia, K. T., de Jong, A. C., van Dessel, L. F., de Weerd, V., Beaufort, C., Helmijr, J., Nakauma-González, J. A., van Riet, J., Hamberg, P., Vis, D., van der Heijden, M. S., Beije, N., Lolkema, M. P., Deger, T., Wilting, S. M., de Wit, R., Jansen, M. P. H. M., & Martens, J. W. M. (2025). Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.13797

Vancouver

Isebia KT, de Jong AC, van Dessel LF, de Weerd V, Beaufort C, Helmijr J, et al. Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer. Molecular Oncology. 2025. doi:10.1002/1878-0261.13797

BibTeX
@article{Isebia2025,
  author = {Isebia, Khrystany T and de Jong, Anouk C and van Dessel, Lisanne F and de Weerd, Vanja and Beaufort, Corine and Helmijr, Jean and Nakauma-González, José Alberto and van Riet, Job and Hamberg, Paul and Vis, Daniel and van der Heijden, Michiel S and Beije, Nick and Lolkema, Martijn P and Deger, Teoman and Wilting, Saskia M and de Wit, Ronald and Jansen, Maurice P H M and Martens, John W M},
  title = {Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer},
  journal = {Molecular Oncology},
  year = {2025},
  doi = {10.1002/1878-0261.13797}
}
Kostenlos starten →